

# Efficacy of Short-Term Corticosteroid on Azithromycin-Refractory *Mycoplasma Pneumoniae* Infection in Pediatric Out-Patients

Masayuki Nagasawa<sup>1,2\*</sup> and Hideo Ohbayashi<sup>2</sup>

<sup>1</sup>Department of Pediatrics and Developmental Biology, Institute of Science Tokyo, 1-5-45 Bunkyo-ku, Tokyo 113-8519, Japan

<sup>2</sup>Ohbayashi Medical Clinic, 656-1 Sendano, Shiraoka-city, Saitama 349-0215, Japan

\*Corresponding author: Masayuki Nagasawa, Ohbayashi Medical Clinic, 656-1 Sendano, Shiraoka-city, Saitama 349-0215, Japan.  
E-mail: mnagasawa.ped@tmd.ac.jp

## ARTICLE INFO

Received: 📅 March 16, 2026

Published: 📅 March 25, 2026

**Citation:** Masayuki Nagasawa and Hideo Ohbayashi. Efficacy of Short-Term Corticosteroid on Azithromycin-Refractory *Mycoplasma Pneumoniae* Infection in Pediatric Out-Patients. Biomed J Sci & Tech Res 65(1)-2026. BJSTR. MS.ID.010149.

## ABSTRACT

In recent years, the increase in macrolide-refractory *Mycoplasma pneumoniae* (MP) infection, which presents failure to achieve fever resolution within 2–3 days after macrolide administration and is highly related with 23S rRNA mutations, has become a problem. We retrospectively reviewed the treatment details in pediatric out-patients with PCR determined MP infection and found that short-term combination therapy with prednisolone (0.4–0.8 mg/kg/day) for three days is useful as treatment for azithromycin-refractory MP infection.

**Keywords:** *Mycoplasma Pneumoniae*, Macrolide-Refractory, Corticosteroid

**Abbreviations:** MP: *Mycoplasma pneumoniae*; RO: Reproduction Number; AZM: Azithromycin; CAM: Clarithromycin; MINO: Minocycline; TFLX: Tosufloxacin; PSL: Prednisolone

*Mycoplasma pneumoniae* (MP) is the most common causative pathogen of community-acquired pneumonia in children aged 5 years and older and young adults. Prior to the COVID-19 pandemic, a cyclical epidemic pattern appeared approximately every 1-4 years [1]. The incubation period is relatively long at two to three weeks, and the basic reproduction number (R0), an indicator of infectiousness, is  $R_0 = 1.7$  (95% CI: 1.6-1.9). This leads to outbreaks within relatively small groups such as families and schools [2]. This suggests that unlike respiratory viral infections with short incubation periods and high infectivity, it tends to begin as localized regional outbreaks. Since they lack cell walls and are intracellular parasites, bacteriostatic antibiotics such as macrolides, tetracyclines, and fluoroquinolones are used for treatment. The rate of proliferation within cells is slow, taking approximately 6 hours—a very slow pace compared to the typical 20 to 30 minutes for most bacteria. Therefore, in the pathogenesis, the direct damage caused by pathogen proliferation is considered to be a minor factor, while the host's immune response plays a major role. Regarding the immune response in MP pneumonia, an interest-

ing report comes from a group at the University Children's Hospital (Zurich) [3,4].

They examined the number of MP-specific IgM-producing B cells (IgM-ASC) as a humoral immune response and the number of MP-specific IFN- $\gamma$ -producing CD4+ T cells (IFN- $\gamma$ -CD4+) as a cellular immune response using spot-ELISA. IgM-ASC levels surge sharply in the early disease phase and decline rapidly, whereas IFN- $\gamma$ -CD4+ T cells increase during the acute phase, persist, and correlate with disease severity. As a result, complications can include a wide variety of conditions such as otitis media, aseptic meningitis, encephalitis, hepatitis, pancreatitis, hemolytic anemia, myocarditis, arthritis, Guillain-Barré syndrome, and Stevens-Johnson syndrome [5]. Inactivated and attenuated vaccines have been attempted, but reports indicate that vaccination can exacerbate symptoms after infection (so-called vaccine-enhanced disease: VED) [6]. To date, no effective vaccine is available. MP infections are generally mild and considered self-limiting. In recent years, the increase in macrolide-resistant *Mycoplasma pneumoniae* has become a problem, particularly in Asia. In China es-

pecially, nearly all *Mycoplasma pneumoniae* detected in clinical specimens are reported to be macrolide-resistant, and severe MP infections have become a significant concern [7,8]. Resistance is mediated predominantly via point mutation within domain V of the 23SrRNA at position 2063 or 2064, preventing drug binding. It has been reported that failure to achieve fever resolution within 2–3 days after macrolide administration correlates with macrolide resistance with 23SrRNA mutations [9].

Most reports on the treatment of macrolide-resistant MP have focused on hospitalized patients. Numerous reports indicate the effectiveness of corticosteroid treatment for severe cases [10,11]. From May to October 2025, there were 141 pediatric patients (7.84 ± 3.19 years old) diagnosed as MP infection through PCR testing at our medical clinic. All cases improved with outpatient treatment without hospitalization. We retrospectively reviewed the treatment details and

their clinical efficacy (summarized in Table 1). Initial treatment failure is defined as “no fever resolution by the third day of treatment initiation and no improvement in the patient’s clinical symptoms.” As initial treatment, azithromycin (AZM) was selected for 69 patients (48.9%), clarithromycin (CAM) for 25 patients (17.0%), minocycline (MINO) for 39 patients (27.7%), and tosylflouxacin (TFLX) for 8 patients (5.7%). Twenty-three patients (16.3%) failed to respond to initial treatment and required secondary treatment. Regarding the initial treatment efficacy with monotherapy, MINO was effective in all cases. Secondary treatment was required in half of cases (16/32) with AZM monotherapy. CAM tended to be selected for mild cases. In the initial treatment AZM group, patients receiving prednisolone (PSL) had a significantly longer pre-treatment fever (>38.0°C) duration (3.32 vs 5.57 days) and tended to be more severe compared to those not receiving PSL.

**Table 1.**

Initial Treatment	n	Age (Years)*	Pre-Treatment Fever Duration (Days)**	Initial Treatment Failure
AZM	32	7.91 ± 2.97	3.32 ± 2.51	16
AZM + PSL	37	6.92 ± 2.21	5.57 ± 1.86	0
MINO	30	9.63 ± 2.39	4.30 ± 2.22	0
MINO + PSL	9	11.11 ± 0.74	5.33 ± 2.88	0
CAM	24	6.29 ± 4.25	2.73 ± 2.49	6
CAM + PSL	1	1	0	0
TFLX	7	5.86 ± 2.17	3.14 ± 2.29	1
TFLX + PSL	1	7	10	0

Note: AZM: Azithromycin, MINO: Minocycline, CAM: Clarithromycin, TFLX: Tosylflouxacin, PSL: Prednisolone

\*: mean ± SD, \*\*: mean ± SD

However, no cases of initial treatment failure were observed in the AZM group receiving PSL. All 10 patients with initial treatment failure in AZM monotherapy group who received secondary treatment with PSL alone also showed prompt improvement. There were no significant differences in age (8.00 vs 7.81 years-old) or pre-treatment fever duration (3.38 vs 3.25 days) between the responders and non-responders in the AZM monotherapy initial treatment group. PSL was administered at 0.4–0.8 mg/kg/day (maximum: 30 mg/day) for 3 days in all cases. Although genetic examination of the presence or absence of 23SrRNA mutations for azithromycin-refractory MP could not be performed in this study, our findings indicate that short-term combination therapy with PSL is useful as treatment for out-patients with AZM-refractory MP infection and warrants further investigation.

### Author Contribution

The authors confirm contribution to the paper as follows: Conception, design, literature review, draft manuscript, preparation and

approval: MN, preparation and approval: HO. The authors reviewed the results and approved the final version of the manuscript.

### Ethics Committee Approval

This paper’s content is approved by the institutional review board (2025/11/1, 2025-1101).

### Conflicts of Interest

The authors declare that there is no conflict of interest to disclose.

### Funding

The authors declare that the study received no funding.

### Data Availability

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

## References

1. Beeton ML, Zhang XS, Uldum SA, Bébéar C, Dumke R, et al. (2020) Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. Euro Surveill 25(2): 1900112.
2. Rowlands RS, Meyer Sauter PM, Beeton ML (2024) Mycoplasma pneumoniae: not a typical respiratory pathogen. J Med Microbiol 73(10): 001910.
3. Meyer Sauter PM, Seiler M, Trück J, Unger WWJ, Paioni P, et al. (2019) Diagnosis of *Mycoplasma pneumoniae* Pneumonia with Measurement of Specific Antibody-Secreting Cells. Am J Respir Crit Care Med 200(8): 1066-1069.
4. Pánisová E, Unger WWJ, Berger C, Meyer Sauter PM (2021) Mycoplasma pneumoniae-Specific IFN- $\gamma$ -Producing CD4(+) Effector-Memory T Cells Correlate with Pulmonary Disease. Am J Respir Cell Mol Biol 64(1): 143-146.
5. Georgakopoulou VE, Lempesis IG, Sklapani P, Trakas N, Spandidos DA (2024) Exploring the pathogenetic mechanisms of Mycoplasmapneumoniae (Review). Exp Ther Med 28(1): 271.
6. Smith CB, Chanock RM, Friedewald WT, Alford RH (1967) Mycoplasma pneumoniae infections in volunteers. Ann N Y Acad Sci 143(1): 471-483.
7. Pereyre S, Goret J, Bébéar C (2016) *Mycoplasma pneumoniae*: Current Knowledge on Macrolide Resistance and Treatment. Front Microbiol 7: 974.
8. Nagasawa M (2025) Verification of Immune Debts in Children Caused by the COVID-19 Pandemic from an Epidemiological and Clinical Perspective. Immuno 5(1): 5.
9. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, et al. (2006) Clinical evaluation of macrolide-resistant *Mycoplasma pneumoniae*. Antimicrob Agents Chemother 50(2): 709-712.
10. Ding G, Zhang X, Vinturache A, van Rossum AMC, Yin Y, et al. (2024) Challenges in the treatment of pediatric *Mycoplasma pneumoniae* pneumonia. Eur J Pediatr 183(7): 3001-3011.
11. Liu J, He R, Zhang X, Zhao F, Liu L, et al. (2023) Clinical features and "early" corticosteroid treatment outcome of pediatric *mycoplasma pneumoniae* pneumonia. Front Cell Infect Microbiol 13: 1135228.

ISSN: 2574-1241

DOI: 10.26717/BJSTR.2026.65.010149

Masayuki Nagasawa. Biomed J Sci & Tech Res



This work is licensed under Creative Commons Attribution 4.0 License

Submission Link: <https://biomedres.us/submit-manuscript.php>



### Assets of Publishing with us

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<https://biomedres.us/>